Combination for the therapy of benign prostatic hyperplasia

Abstract

This invention relates to a novel method for the treatment of the symptoms associated with benign prostatic hyperplasia currently employed for the medical therapy of benign prostatic hyperplasia. This entails concurrent use of : (1) an α-1 adrenoceptor antagonist in controlled-release formulation or a 5-α reductase inhibitor and (2) a cGMP PDE 5 inhibitor in controlled-release formulation or a cGMP PDE 5 inhibitor with a long half-life.